

1 **Title:** *EHR-based Case Identification of Pediatric Long COVID: A Report from the RECOVER*

2 *EHR Cohort*

3 **Authors:**

4 Morgan Botdorf, PhD¹, Kimberley Dickinson, BS¹, Vitaly Lorman PhD¹, Hanieh Razzaghi,
5 PhD¹, Nicole Marchesani, MS¹, Suchitra Rao, MBBS, MSCS², Colin Rogerson, MD³, Miranda
6 Higginbotham, MHA¹, Asuncion Mejias, MD, PhD, MsCS⁴, Daria Salyakina, PhD⁵, Deepika
7 Thacker, MD⁶, Dima Dandachi, MD, MPH⁷, Dimitri A Christakis MD MPH⁸, Emily Taylor,
8 M.A.⁹, Hayden Schwenk, MD, MPH¹⁰, Hiroki Morizono, PhD¹¹, Jonathan Cogen MD, MPH¹²,
9 Nate M Pajor MD, MS¹³, Ravi Jhaveri, MD¹⁴, Christopher B. Forrest, MD, PhD¹, L. Charles
10 Bailey, MD, PhD¹, *on behalf of the RECOVER Consortium* □

11
12 **Affiliations:** □ □ □

13 ¹ Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA □

14 ² Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital
15 Colorado, Denver, CO

16 ³ Division of Critical Care, Department of Pediatrics, Indiana University School of Medicine,
17 Indianapolis, IN

18 ⁴ Division of Infectious Diseases, Department of Pediatrics, Nationwide Children's Hospital and
19 The Ohio State University, Columbus, OH

20 ⁵ Center for Precision Medicine, Nicklaus Children's Hospital, Miami, FL

21 ⁶ Nemours Cardiac Center, Alfred I. duPont Hospital for Children, Wilmington, DE.

22 ⁷ Division of Infectious Diseases, Department of Medicine, University of Missouri-Columbia,
23 Columbia, MO

24 ⁸ Center for Child Health, Behavior and Development, Seattle Children's Research Institute,
25 Seattle, WA

26 ⁹ New York University Grossman School of Medicine Department of Medicine New York, NY

27 ¹⁰ Stanford School of Medicine, Division of Pediatric Infectious Diseases, Stanford, CA

28 ¹¹ Center for Genetic Medicine Research, Children's National Hospital, Washington, DC

29 ¹² Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children's
30 Hospital, University of Washington, Seattle, WA

31 ¹³ Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and University
32 of Cincinnati College of Medicine, Cincinnati OH

33 ¹⁴ Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago,
34 Chicago, IL

35
36 **Authorship Statement**

37 Authorship has been determined according to ICMJE recommendations.

38

39 **Corresponding Author:**

40 Name: Morgan Botdorf

41 Affiliation: Applied Clinical Research Center, Children's Hospital of Philadelphia

42 Email: botdorfm@chop.edu

43 **Abbreviated Title:** Identifying Children with Long COVID

44 **Funding Source:** This research was funded by the National Institutes of Health (NIH)

45 Agreement OTA OT2HL161847-01 as part of the Researching COVID to Enhance Recovery
46 (RECOVER) program of research.

47 **Disclaimer:** This content is solely the responsibility of the authors and does not necessarily
48 represent the official views of the RECOVER Initiative, the NIH, or other funders.

49

50 **Key Words:** PEDSnet, Post-acute sequelae SARS-CoV-2 infection, Long COVID, Chronic
51 COVID-19 Syndrome, Late sequelae of COVID-19, Long haul COVID, Long-term COVID-19,
52 Post COVID syndrome, Post-acute COVID-19, Rule-based phenotyping, Electronic health
53 records, Electronic phenotyping, Chart review

54 **Abbreviations:** PASC—post-acute sequelae of SARS-CoV-2 infection; COVID-19—
55 coronavirus disease 2019; SARS-CoV-2—severe acute respiratory syndrome coronavirus 2;
56 PCR—polymerase chain reaction; EHR—electronic health record; MIS-C—multisystem
57 inflammatory syndrome in children; ICD-10—International Classification of Diseases, version
58 10.

59

60 **Abstract**

61 **Objective**

62 Long COVID, marked by persistent, recurring, or new symptoms post-COVID-19 infection,
63 impacts children's well-being yet lacks a unified clinical definition. This study evaluates the
64 performance of an empirically derived Long COVID case identification algorithm, or
65 computable phenotype, with manual chart review in a pediatric sample. This approach aims to
66 facilitate large-scale research efforts to understand this condition better.

67 **Methods**

68 The algorithm, composed of diagnostic codes empirically associated with Long COVID, was
69 applied to a cohort of pediatric patients with SARS-CoV-2 infection in the RECOVER PCORnet
70 EHR database. The algorithm classified 31,781 patients with conclusive, probable, or possible
71 Long COVID and 307,686 patients without evidence of Long COVID. A chart review was
72 performed on a subset of patients ($n=651$) to determine the overlap between the two methods.
73 Instances of discordance were reviewed to understand the reasons for differences.

74 **Results**

75 The sample comprised 651 pediatric patients (339 females, $M_{age} = 10.10$ years) across 16
76 hospital systems. Results showed moderate overlap between phenotype and chart review Long
77 COVID identification (accuracy = 0.62, PPV = 0.49, NPV = 0.75); however, there were also
78 numerous cases of disagreement. No notable differences were found when the analyses were
79 stratified by age at infection or era of infection. Further examination of the discordant cases
80 revealed that the most common cause of disagreement was the clinician reviewers' tendency to
81 attribute Long COVID-like symptoms to prior medical conditions. The performance of the

82 phenotype improved when prior medical conditions were considered (accuracy = 0.71, PPV =
83 0.65, NPV = 0.74).

84 **Conclusions**

85 Although there was moderate overlap between the two methods, the discrepancies between the
86 two sources are likely attributed to the lack of consensus on a Long COVID clinical definition. It
87 is essential to consider the strengths and limitations of each method when developing Long
88 COVID classification algorithms.

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105 **Introduction**

106 Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), is a
107 significant health concern characterized by ongoing, relapsing, or new symptoms emerging four
108 or more weeks after the acute infection phase¹. While post-viral syndromes like chronic fatigue
109 syndrome following mononucleosis are well-documented in children²⁻³, understanding the
110 clinical manifestations of Long COVID in pediatric patients remains incomplete. The variability
111 of symptoms in children compared to adults complicates diagnosis and treatment⁴⁻⁹. Symptoms
112 can range from fatigue and headache to loss of taste and smell and chest pain⁴⁻⁹. Although rare,
113 diagnosed conditions associated with Long COVID include myocarditis, myositis, postural
114 tachycardia syndrome (POTS), and myalgic encephalomyelitis/chronic fatigue syndrome
115 (ME/CFS), among other conditions¹⁰. Despite certain symptoms and conditions clearly
116 attributable to a SARS-CoV-2 infection, like multisystem inflammatory syndrome (MIS-C),
117 much remains to be understood about others¹¹⁻¹². These symptoms and conditions impose a
118 substantial burden on children and their families, leading to missed school and the need for
119 service referrals¹³⁻¹⁴. This highlights the importance of improved detection and treatment
120 strategies.

121 Identifying children who suffer from Long COVID in research studies is crucial to better
122 understand this disorder and ensuring timely detection and treatments in clinical settings.
123 However, this task is challenging due to the inconsistency and heterogeneity of associated
124 symptoms. To address this challenge, researchers have used large observational cohort studies
125 that use repositories of electronic health record (EHR) data to identify patients^{5, 8, 9, 15, 16}. These
126 studies have primarily relied on EHR-based diagnosis codes¹⁵⁻¹⁶. The ICD-10-CM U09.9 code,
127 introduced in October 2021¹⁷⁻¹⁸, allows clinicians to assign a Long COVID diagnosis; however,

128 its utilization remains inconsistent and potentially biased across patients and healthcare settings
129 ¹⁶. Additionally, relying solely on this code may not adequately capture all patients due to the
130 variety of symptoms associated with Long COVID. This poses a risk of misclassification if
131 researchers exclusively use the U09.9 code for phenotyping.

132 To improve identification of patients with Long COVID, computable phenotyping
133 techniques, which involve developing a set of rules to identify patients with a disorder, have
134 been used in Long COVID studies. Long COVID phenotypes for adult¹⁹ and pediatric²⁰ patients
135 have been developed using machine-learning approaches that leverage large numbers of clinical
136 features. For example, in a recent pediatric study, a machine learning algorithm demonstrated
137 high precision in classifying both general and MIS-C-specific forms of PASC, with recall rates
138 of up to 70% ²⁰. Training these supervised learning models requires a labeled cohort of patients
139 who likely have Long COVID based on healthcare utilization or Long COVID diagnosis codes.
140 Since there is no gold-standard definition of Long COVID, it is difficult to produce an unbiased
141 labeled training set, which limits the generalizability of the models.

142 In this study, we aimed to 1) identify children with Long COVID by utilizing a rules-
143 based computable phenotype approach and 2) assess the performance of this computable
144 phenotype for Long COVID in a subset of children. This approach involves analyzing specific
145 diagnosis coding and symptoms that occur more frequently after a COVID-19 infection. By
146 doing so, we can more accurately identify a larger number of children with Long COVID. In
147 addition, we have included clinician reviews of patient charts to gain a comprehensive
148 understanding of patients' experience with Long COVID. This combined approach represents a
149 significant step in the automation of Long COVID clinical phenotypes using EHR data in the
150 absence of a consensus definition.

151 **Methods**

152 *Data Source*

153 This retrospective cohort study is part of the NIH Researching COVID to Enhance
154 Recovery (RECOVER) Initiative, which seeks to understand, treat, and prevent the post-acute
155 sequelae of SARS-CoV-2 infection²¹. The RECOVER PCORnet EHR cohort includes clinical
156 data from patients in 40 hospital systems across the United States. Data were extracted from
157 version 6 of the pediatric RECOVER database, comprising more than 9 million children who
158 were tested for SARS-CoV-2, diagnosed with COVID-19, or received a COVID-19 vaccine
159 between 2019 and December 2022. Institutional Review Board (IRB) approval was obtained
160 under Biomedical Research Alliance of New York (BRANY) protocol #21-08-508. BRANY
161 waived the need for consent and HIPAA authorization.

162 *Study Population*

163 Inclusion criteria for our pediatric sample were as follows: 1) SARS-CoV-2 infection
164 confirmed via clinical diagnosis or PCR, antigen, or qualifying serology test²² between March
165 2020 and December 2022, 2) age less than 21 years at first COVID-19 infection, and 3) at least
166 two contacts with the healthcare system (at least one being in-person or telehealth) to ensure
167 adequate follow-up during the post-acute phase (28-179 days following infection). We defined
168 clinically meaningful time periods surrounding the initial COVID-19 infection as shown in
169 Figure 1. The acute phase spanned until the 27th day post-infection. The post-acute phase, which
170 was the primary focus of our analyses, spanned from day 28 through day 179 post-infection,
171 ensuring that symptoms were not directly related to the acute COVID-19 infection. For patients
172 with a specific COVID-19 diagnosis or viral test, the initial infection date was the date of
173 diagnosis or test. For patients with diagnoses indicating “history of” or “complication of”

174 COVID-19 or with a positive serology test, we used 28 days prior to the earliest diagnosis or test
175 evidence of COVID-19 as a proxy for initial infection date.

176 *Phenotype classification*

177 Patients were identified as having conclusive, probable, or possible Long COVID
178 according to the algorithm described in Figure 2, which used criteria documented in the EHR in
179 the post-acute period. The algorithm accounts for diagnoses of Long COVID (ICD-10-CM code
180 U09.9), diagnoses of MIS-C (ICD-10-CM code M35.81), diagnoses of sequelae of specified
181 infectious and parasitic diseases (ICD-10-CM code B94.8), and 23 diagnosis clusters identified
182 as probable indicators of Long COVID based on our prior work^{5,9} (Supplemental File 1). The
183 diagnosis clusters were formed using a data mining approach that identified conditions more
184 common in U09.9-diagnosed patients than in non-U09.9 diagnosed COVID-19+ patients in the
185 post-acute period⁵. Clinicians then reviewed the diagnosis codes to create clusters of ICD-10-CM
186 codes. Clusters included abdominal pain, abnormal liver enzymes, acute kidney injury, acute
187 respiratory distress syndrome, arrhythmias, autonomic dysfunction, cardiovascular
188 signs/symptoms, changes in taste/smell, chest pain, cognitive function, generalized pain,
189 fatigue/malaise, fever, fluid/electrolyte balance, headache, heart disease, myocarditis,
190 musculoskeletal symptoms, myositis, respiratory signs/symptoms, and
191 thrombophlebitis/thromboembolism. Any patient with two or more diagnoses within the same
192 cluster separated by at least 28 days during the post-acute period was labeled as having probable
193 Long COVID, regardless of whether the patient had a specific Long COVID or MIS-C diagnosis
194 code. Figure 2 depicts the steps applied to classify patients according to the certainty of them
195 having Long COVID. Any patient with conclusive, probable, or possible Long COVID detected

196 by the phenotype was labeled as “Long COVID Evidence” and all others were labelled as “No
197 Long COVID Evidence”.

198 *Chart Review Sampling*

199 A manual chart review was performed on a subset of the study population at 16
200 institutions. We sampled 702 patients split between the Long COVID Evidence and No Long
201 COVID Evidence groups to ensure there was adequate representation across sites. The sampling
202 strategy is laid out in Figure 3. Approximately 22 Long COVID Evidence patients were
203 randomly sampled per institution. Each Long COVID Evidence sampled patient was matched
204 1:1 without replacement with a No Long COVID Evidence patient using exact matching on
205 institution, age at time of infection, calendar quarter of infection, and acute period hospitalization
206 (yes/no). Ninety percent of the No Long COVID Evidence sample had SARS-CoV-2 infection
207 while the remaining ten percent (35 patients) were patients with no evidence of SARS-CoV-2 but
208 with at least two diagnoses of cluster conditions separated by 28 to 150 days. The latter group
209 were additional patients included in the chart review to gather insight on the attribution of cluster
210 diagnoses to conditions other than SARS-CoV-2 infection. A total of 651 children were
211 ultimately included in analyses based on additional exclusions which will be discussed. The
212 sampling strategy is laid out in Figure 3.

213 *Chart Review Procedure*

214 Clinical research teams from each participating institution conducted chart reviews using
215 a REDCap²³ (Research Electronic Data Capture) instrument with questions including
216 information on COVID-19 diagnoses and testing, demographics, COVID-19 prevention and
217 treatment strategies, vaccines, functional outcomes, and conditions post COVID-19 captured in
218 the patient’s medical record. Each site had between 1 and 5 reviewers for a total of 44 reviewers

219 across sites. Table 1 contains a summary of patient information extracted from chart review, and
220 the full case report form is included in Supplemental File 2.

221 A secondary review was completed by a clinician who reviewed information extracted by
222 the primary chart reviewer and answered questions regarding the level of confidence with which
223 Long COVID could be assigned to the patient. The clinician was first asked if the patient met
224 criteria for Long COVID based on the NIH definition²¹ which describes Long COVID as signs,
225 symptoms, and conditions that continue or develop after initial COVID-19 or SARS-CoV-2
226 infection, are present four weeks [28 days] or more after the initial phase of infection; may be
227 multisystemic; and may present with a relapsing-remitting pattern and progression or worsening
228 over time, with the possibility of severe and life-threatening events even months or years after
229 infection. They were then asked if the patient met criteria for Long COVID based on the
230 computable phenotype definition. The response to these questions (i.e., conclusive, probable,
231 possible, no evidence) was used to assess concordance with the computable phenotype. The first
232 question, which analyses focused on, asked the clinician to exercise clinical judgment, while the
233 second question was focused on assessing the validity of the structured EHR data.

234 For ease of assessing the performance of the computable phenotype compared with chart
235 review, patients were collapsed into four overlapping groups: computable phenotype-positive
236 (CP-positive), computable phenotype-negative (CP-negative), clinician review-positive (CR-
237 positive), and clinician review-negative (CR-negative). Patients identified by the phenotype as
238 having conclusive or probable Long COVID were placed in the CP-positive group. Conversely,
239 patients found to have possible evidence or no evidence of Long COVID were placed in the CP-
240 negative group. Patients with possible Long COVID were included in the CP-negative sample as
241 the study team concluded that having only one post-viral sequelae code without a positive PCR

242 test to confirm SARS-CoV-2 infection did not provide enough evidence to conclude that the
243 patient's post-viral sequelae was caused by Long COVID. On the other hand, when examining
244 the chart review, we determined that the reasons reviewers used to classify patients as possible
245 for Long COVID were more similar to a positive than a negative Long COVID classification.
246 Therefore, the CR-positive group consisted of patients labeled as conclusive, probable, or
247 possible for Long COVID by the clinician reviewer. In contrast, the CR-negative group consisted
248 of patients labeled as having no evidence of Long COVID by the clinician reviewer.

249 *Performance Assessment*

250 The performance of the computable phenotype was evaluated across various key metrics
251 including sensitivity, specificity, positive predictive value (PPV), and negative predictive value
252 (NPV). Additionally, we examined the accuracy and F1 score of the phenotype. Accuracy
253 assesses the proportion of CR-positive patients who were also CP-positive. The F1 score
254 combines precision and recall providing insight into the overall effectiveness of the phenotype.

255 Next, we assessed whether concordance between the phenotype and clinician review
256 classification differed by age (i.e., under vs. over 12 years old), variant period (i.e., alpha, delta,
257 omicron), and number of symptom clusters through stratified analyses. Analyses were conducted
258 using R version 4.1.2 (2021-11-01; 24).

259 We conducted an assessment to identify discrepancies between the phenotype and chart
260 review identification of Long COVID. We reviewed cases where the phenotype identified Long
261 COVID, but the chart review did not, and vice versa. To understand the reasons behind these
262 discrepancies, we reviewed the chart review form for each discordant patient, along with the
263 clinician reviewer's explanation for assigning or not assigning Long COVID. We then generated
264 themes that accounted for the discrepancy and assigned those themes to the remaining cases. We

265 next aimed to modify our model based the most common themes and perform a sensitivity
266 analysis to assess whether the performance of our modified model was superior to our original
267 model.

268 To describe the sample and investigate the impact of patients with complex medical
269 histories on the performance of the phenotype, we used the Pediatric Medical Complexity
270 Algorithm²⁵ (PMCA). We determined the chronic condition status of each patient by applying
271 the more conservative version of the algorithm. This version requires that a patient have one
272 diagnosis of a progressive or malignant condition or at least two diagnoses per body system for
273 at least two body systems in the three years prior to the SARS-CoV-2 infection.

274 **Results**

275 Among patients with a positive SARS-CoV-2 infection (1,007,867), the computable
276 phenotype detected Long COVID in 31,781 (3.2%) patients. Seven hundred and two patients
277 were included in the chart review sample; however, sixteen charts were not completed due to
278 limitations in the chart reviewers' access to records and were excluded from the sample. In
279 addition, the 35 patients with no evidence of SARS-CoV-2 infection according to the computable
280 phenotype were not included in comparative analyses as a full chart review was not completed
281 on them. Thus, our final sample consisted of 651 patients. Sample demographics and descriptive
282 statistics are presented in Table 1. Sociodemographic characteristics were similar among those
283 classified with and without Long COVID by the phenotype and by the clinician chart reviewer
284 (Supplemental Table S1).

285 There was 73.33% agreement between the responses to the two questions the clinician
286 chart reviewers answered. Table 2 presents statistics assessing the performance of the
287 computable phenotype with chart review. The two methods had substantial but incomplete

288 overlap. Analyses assessing whether concordance differed by selected variables showed similar
289 results across age, era associated with infection, and number of symptom clusters (Supplemental
290 Tables S2-4).

291 *Computable Phenotype-Only and Clinician Review-Only Long COVID Positive Review*

292 A review was conducted to assess the reasons for disagreement between the two methods.
293 The initial focus was cases where the phenotype identified Long COVID, but the chart review
294 did not (CP+/CR- cases) as there were many of these cases. Results are presented in Figure 4. In
295 most CP+/CR- cases, the clinician reviewer agreed with the symptoms the computable
296 phenotype identified but attributed those symptoms to another viral infection or preexisting
297 disorder (Figure 4a). This was especially true for symptoms common to other respiratory
298 infections and symptoms with occurrences both pre and post COVID-19 infection. In other less
299 common cases, the reviewer did not see the diagnostic codes that the phenotype saw, or the
300 reviewer made a conclusion based on incomplete information.

301 An assessment of CR+/CP- cases showed that in many cases the reviewer considered
302 symptoms, visits, and time frames that differed from our phenotype (Figure 4b). For example,
303 clinician reviewers considered symptoms beyond 180 days post-infection (up to 11 months in
304 some cases) while the computable phenotype considered symptoms in the one month to 180 days
305 following infection. In addition, reviewers considered symptoms beyond those included in the
306 computable phenotype definition, such as mental health symptoms. For example, clinician
307 reviewers used clinical judgment and identified anxiety as a qualifying symptom, but it is not
308 included in the phenotype definition due to inconsistent recording in structured data.

309 *Sensitivity Analysis*

310 The review of CP+/CR- patients showed that comorbidities were a large factor
311 contributing to discordance between the two methods. Given the difficulty of distinguishing
312 symptoms due to preexisting conditions and symptoms due to Long COVID, we performed a
313 sensitivity analysis to assess concordance with a modified model in which preexisting conditions
314 and comorbidities were accounted for. First, we censored prior symptoms. In other words, we
315 assessed phenotype classification when non-incident diagnoses were excluded. Patients who met
316 criteria for the computable phenotype with only preexisting symptom clusters that persisted after
317 their COVID-19 diagnosis were labeled as having no evidence of Long COVID (n = 32 patients).
318 Second, given the high prevalence of symptoms reported in the setting of non-COVID-19
319 respiratory infections, we excluded respiratory or fever cluster diagnoses that occurred 2 weeks
320 prior to or after a diagnosis of a non-COVID-19 respiratory infection. This led to exclusion of 31
321 patients who did not otherwise meet the criteria for probable long COVID. Finally, it was
322 difficult to attribute post-acute symptoms to a COVID-19 diagnosis versus underlying medical
323 conditions in patients with multiple chronic medical conditions. Therefore, we identified patients
324 with complex medical histories using the PMCA²⁵. We reclassified patients with a complex
325 chronic condition as having no evidence of Long COVID (n = 67 patients) as we believed that
326 our phenotype could not accurately identify these patients as having Long COVID.

327 Concordance was assessed again after incorporating these alterations into a modified
328 model, and results showed a higher positive predictive value and specificity but lower sensitivity
329 (Table 3). The negative predictive value remained high. Given the difficulty in adequately
330 attributing diagnoses to Long COVID in patients with complex medical histories, we also
331 completed a sensitivity analysis where these patients were removed from the sample, and

332 performance was reassessed (Table 3). Results showed similar performance to the modified
333 model overall, but a higher F1 score.

334 **Discussion**

335 We conducted a study to assess the performance of a rules-based computable phenotype
336 for identifying pediatric patients with Long COVID in a large EHR database compared to
337 clinician chart review. Results showed moderate overlap between the two methods. Specifically,
338 the computable phenotype was moderately sensitive in detecting patients with Long COVID and
339 specific in detecting those without Long COVID, in comparison to chart review. However, there
340 were several cases where the methods disagreed, with some patients being classified as having
341 Long COVID by the phenotype but not by chart review, and vice versa. The main reason for
342 these discrepancies was due to underlying comorbidities and subsequent respiratory infections.

343 Patients with comorbidities posed a challenge for the computable phenotype and the
344 clinician reviewer. This was likely due to the lack of clinical guidelines for attribution and the
345 difficulty in discerning exacerbation of preexisting symptoms. Clinicians were more likely to
346 attribute post-COVID-19 symptoms to preexisting conditions when comorbidities were present,
347 which likely resulted in the misattribution of Long COVID symptoms and may have been
348 influenced by the provider involved in clinical care. However, the overlap between the two
349 methods increased when the CP accounted for preexisting medical conditions by focusing on
350 incident diagnoses and censoring existing conditions. Nevertheless, because our phenotype was
351 not initially designed to assess exacerbation of preexisting conditions, we caution against its use
352 to diagnose Long COVID in patients with medical complexity. Another source of disagreement
353 between the computable phenotype and chart review stemmed from subsequent non-COVID-19
354 respiratory infections, which are common in children. Although there may be an increased risk of

355 secondary infections due to SARS-CoV-2²⁶⁻²⁷, the symptoms are caused by a different agent.
356 Therefore, we removed these circumstances as indicators of Long COVID in our phenotype.

357 An analysis of chart review-only positives (i.e., those the clinician reviewer classified as
358 having Long COVID that the phenotype did not) showed that differences in the computable
359 phenotype guidelines and the clinician's framework for identifying Long COVID were the main
360 reasons for discordance. While the computable phenotype only assessed symptoms up to 180
361 days post SARS-CoV-2 infection, clinicians may use a longer time window in practice. This
362 suggests an extended time frame for assessing post-acute symptoms may be necessary, but also
363 may increase the risk of later onset of symptoms not being clearly attributable to a SARS-CoV-2
364 infection. In addition, clinician reviewers identified conditions beyond those included in our
365 phenotype as providing evidence for Long COVID. For example, the computable phenotype did
366 not consider mental health conditions due to reporting inconsistency of these conditions using
367 diagnosis codes and the difficulty in distinguishing between biologic and social causes of mental
368 health conditions. However, clinicians tended to include them in their framework for identifying
369 Long COVID. Therefore, constructing computable phenotypes that incorporate subphenotypes of
370 interest (e.g., physiological vs psychological manifestations of Long COVID) may be useful in
371 accounting for different manifestations of Long COVID.

372 Many of the differences in identifying Long COVID are due to the lack of a clear and
373 consistently used definition for Long COVID. The novelty of Long COVID in children, as well
374 as the overlap of symptoms with other acute and chronic disorders such as headache and fatigue,
375 contribute to these differences. Similar difficulties have been encountered when defining other
376 post-viral syndromes. Although chart review is often viewed as the best method for detecting
377 patients with a specific disorder, the lack of a consistent definition for Long COVID by

378 healthcare providers poses significant challenges. Moreover, the chart review and EHR research
379 are prone to errors such as biases, missed codes, misdiagnoses, incomplete information due to
380 fragmented care, and a lack of availability of a unique medical code for certain Long COVID-
381 related conditions. For example, a unique ICD code for POTS did not exist until October 2022²⁸,
382 and many clinicians remain unaware of its existence, making it difficult to pick up the presence
383 of POTS in the phenotype or chart review. Therefore, comparing our computable phenotype with
384 chart review provided insight into the clinician's view of a patient's status, but it did not allow us
385 to validate against a gold standard, as we cannot confidently conclude that either method
386 accurately detects Long COVID.

387 Our two-pronged approach to identifying Long COVID using clinician chart review and a
388 computable phenotype is a strength of the study as previous research that used diagnosis codes or
389 machine learning algorithms did not incorporate a review of patient charts¹⁹⁻²⁰. By incorporating
390 both methods, we were able to qualitatively review cases of discordance. In addition, we focused
391 on pediatric patients, in whom Long COVID is understudied. Research suggests that Long
392 COVID has a lower prevalence in children; however, the current diagnostic tools may not be
393 sensitive enough to detect all cases. Our study design is a strength as it uses data-driven
394 symptom clusters for identifying Long COVID and specific diagnosis codes. This approach
395 allowed us to capture patients who may not have a clear Long COVID presentation but have
396 Long COVID-like symptoms. Although it allowed for our phenotype to be more inclusive, it also
397 resulted in a computable phenotype that was less inclusive than a clinician may be when
398 subjectively assessing whether a patient has Long COVID. As more symptoms of Long COVID
399 are identified, it may be necessary to update the symptom clusters.

400 Our study has limitations, but it also brings attention to some significant areas for future
401 work to focus on. Due to the challenge of distinguishing the progression of a chronic condition
402 from symptom exacerbation due to COVID-19 using EHR data and chart review, we were
403 unable to evaluate the worsening of preexisting symptoms. Instead, we examined differences in
404 concordance after excluding pre-COVID-19 symptoms. This approach provided increased
405 certainty that symptoms were due to Long COVID but may have been too restrictive. Future
406 research should consider cluster-specific washout windows and develop reliable methods to
407 identify patients with Long COVID-related worsening of preexisting conditions. Additionally,
408 our sampling strategy focused on edge cases and rare occurrences to develop and refine the
409 phenotype. This approach was useful for identifying patients with a range of Long COVID-
410 related symptoms and diagnoses, but limits generalizability and underestimates the performance
411 of the phenotype. Future iterations should use random sampling to obtain a more generalizable
412 patient sample. Finally, because our study was based on EHR data and we imposed a two-visit
413 requirement in the post-acute period, our sample may be biased towards patients who have the
414 means to obtain healthcare at the population level.

415 **Conclusion**

416 This study describes a computable phenotype approach to identify children with Long
417 COVID in EHR data. Our study highlights the complexity of identifying and diagnosing Long
418 COVID due to its heterogeneity and overlap with other conditions, which leads to substantial
419 differences observed across methods. To address this challenge, future work could include
420 additional data sources, such as unstructured data, and further refine algorithms with clinical
421 expertise to develop a reliable definition of Long COVID. It is also essential to develop a revised
422 phenotype that can identify Long COVID through the worsening of pre-existing conditions. The

423 development of a reliable CP for Long COVID in children allows for studying large data
424 networks, which has future applications for both observational studies and clinical trials. Further
425 research assessing the presentation of Long COVID in children and the interplay between Long
426 COVID and comorbidities is vital to continue to understand this emerging chronic illness and
427 evaluate interventions that can prevent or mitigate its effects.

428

429 **Acknowledgements:**

430 This study is part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative,
431 which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection
432 (PASC). For more information on RECOVER, visit <https://recovercovid.org/>

433

434 We would like to thank the National Community Engagement Group (NCEG), all patient,
435 caregiver, and community Representatives, and all the participants enrolled in the RECOVER
436 Initiative.

437

438 **Author Conflict of Interest Disclosures:** Dr. Mejias reports funding from Janssen, Merck for
439 research support, and Janssen, Merck and Sanofi-Pasteur for Advisory Board participation; Dr.
440 Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris. Dr.
441 Jhaveri is a consultant for AstraZeneca, Seqirus and Dynavax, and receives an editorial stipend
442 from Elsevier. All other authors have no conflicts of interest to disclose.

443 **Role of funder/sponsor statement:** The funder had no role in the design and conduct of the
444 study; collection, management, analysis, and interpretation of the data; preparation, review, or
445 approval of the manuscript; and decision to submit the manuscript for publication.

446

447

448

References

- 449 1. Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re'em, Y., Redfield, S.,
450 Austin, J. P., & Akrami, A. (2021). Characterizing long COVID in an international
451 cohort: 7 months of symptoms and their impact. *eClinicalMedicine*, 38, 101019.
452 <https://doi.org/10.1016/j.eclinm.2021.101019>
- 453 2. Katz, B. Z., Shiraishi, Y., Mears, C. J., Binns, H. J., & Taylor, R. (2009). Chronic Fatigue
454 Syndrome After Infectious Mononucleosis in Adolescents. *Pediatrics*, 124(1), 189–193.
455 <https://doi.org/10.1542/peds.2008-1879>
- 456 3. Sellers, S. A., Hagan, R. S., Hayden, F. G., & Fischer, W. A. (2017). The hidden burden of
457 influenza: A review of the extra-pulmonary complications of influenza infection.
458 *Influenza and Other Respiratory Viruses*, 11(5), 372–393.
459 <https://doi.org/10.1111/irv.12470>
- 460 4. Lopez-Leon, S., Wegman-Ostrosky, T., Ayuzo Del Valle, N. C., Perelman, C.,
461 Sepulveda, R., Rebolledo, P. A., Cuapio, A., & Villapol, S. (2022). Long-COVID in
462 children and adolescents: A systematic review and meta-analyses. *Scientific Reports*,
463 12(1), 9950. <https://doi.org/10.1038/s41598-022-13495-5>
- 464 5. Lorman, V., Rao, S., Jhaveri, R., Case, A., Mejias, A., Pajor, N. M., Patel, P., Thacker,
465 D., Bose-Brill, S., Block, J., Hanley, P. C., Prahalad, P., Chen, Y., Forrest, C. B., Bailey,
466 L. C., Lee, G. M., & Razzaghi, H. (2023). Understanding pediatric long COVID using a
467 tree-based scan statistic approach: An EHR-based cohort study from the RECOVER
468 Program. *JAMIA Open*, 6(1), ooad016. <https://doi.org/10.1093/jamiaopen/ooad016>
- 469 6. Zheng, Y.-B., Zeng, N., Yuan, K., Tian, S.-S., Yang, Y.-B., Gao, N., Chen, X., Zhang,
470 A.-Y., Kondratiuk, A. L., Shi, P.-P., Zhang, F., Sun, J., Yue, J.-L., Lin, X., Shi, L.,

- 471 Lalvani, A., Shi, J., Bao, Y.-P., & Lu, L. (2023). Prevalence and risk factor for long
472 COVID in children and adolescents: A meta-analysis and systematic review. *Journal of*
473 *Infection and Public Health*, 16(5), 660–672. <https://doi.org/10.1016/j.jiph.2023.03.005>
- 474 7. Pellegrino, R., Chiappini, E., Licari, A., Galli, L., & Marseglia, G. L. (2022). Prevalence
475 and clinical presentation of long COVID in children: A systematic review. *European*
476 *Journal of Pediatrics*, 181(12), 3995–4009. <https://doi.org/10.1007/s00431-022-04600-x>
- 477 8. Reese J, Blau H, Bergquist T, Loomba JJ, Callahan T, Laraway B, et al. Generalizable
478 Long COVID Subtypes: Findings from the NIH N3C and RECOVER Program. *MedRxiv*
479 *Prepr Serv Health Sci* 2022:2022.05.24.22275398. [https://doi.or](https://doi.org/10.1101/2022.05.24.22275398)
480 [g/10.1101/2022.05.24.22275398](https://doi.org/10.1101/2022.05.24.22275398) PMID: 35665012
- 481 9. Rao, S., Lee, G. M., Razzaghi, H., Lorman, V., Mejias, A., Pajor, N. M., Thacker, D.,
482 Webb, R., Dickinson, K., Bailey, L. C., Jhaveri, R., Christakis, D. A., Bennett, T. D.,
483 Chen, Y., & Forrest, C. B. (2022). Clinical Features and Burden of Postacute Sequelae of
484 SARS-CoV-2 Infection in Children and Adolescents. *JAMA Pediatrics*, 176(10), 1000.
485 <https://doi.org/10.1001/jamapediatrics.2022.2800>
- 486 10. Rao, S., Gross, R. S., Mohandas, S., Stein, C. R., Case, A., Dreyer, B., Pajor, N. M.,
487 Bunnell, H. T., Warburton, D., Berg, E., Overdevest, J. B., Gorelik, M., Milner, J.,
488 Saxena, S., Jhaveri, R., Wood, J. C., Rhee, K. E., Letts, R., Maughan, C., ... Stockwell,
489 M. S. (2024). Postacute Sequelae of SARS-CoV-2 in Children. *Pediatrics*, 153(3),
490 e2023062570. <https://doi.org/10.1542/peds.2023-062570>
- 491 11. Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B.
492 F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., Singh, A. R.,
493 Li, S., Tarquinio, K. M., Jaggi, P., Oster, M. E., Zackai, S. P., Gillen, J., Ratner, A. J.,

- 494 Walsh, R. F., ... Randolph, A. G. (2020). Multisystem Inflammatory Syndrome in U.S.
495 Children and Adolescents. *New England Journal of Medicine*, 383(4), 334–346.
496 <https://doi.org/10.1056/NEJMoa2021680>
- 497 12. Wu, E. Y., & Campbell, M. J. (2021). Cardiac Manifestations of Multisystem
498 Inflammatory Syndrome in Children (MIS-C) Following COVID-19. *Current Cardiology*
499 *Reports*, 23(11), 168. <https://doi.org/10.1007/s11886-021-01602-3>
- 500 13. Garai, R., Krivácsy, P., Herczeg, V., Kovács, F., Tél, B., Kelemen, J., Máthé, A., Zsáry,
501 E., Takács, J., Veres, D. S., & Szabó, A. J. (2023). Clinical assessment of children with
502 long COVID syndrome. *Pediatric Research*, 93(6), 1616–1625.
503 <https://doi.org/10.1038/s41390-022-02378-0>
- 504 14. Kikkenborg Berg, S., Palm, P., Nygaard, U., Bundgaard, H., Petersen, M. N. S.,
505 Rosenkilde, S., Thorsted, A. B., Ersbøll, A. K., Thygesen, L. C., Nielsen, S. D., &
506 Vinggaard Christensen, A. (2022). Long COVID symptoms in SARS-CoV-2-positive
507 children aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): A
508 national, cross-sectional study. *The Lancet Child & Adolescent Health*, 6(9), 614–623.
509 [https://doi.org/10.1016/S2352-4642\(22\)00154-7](https://doi.org/10.1016/S2352-4642(22)00154-7)
- 510 15. Fritsche, L. G., Jin, W., Admon, A. J., & Mukherjee, B. (2023). Characterizing and
511 Predicting Post-Acute Sequelae of SARS CoV-2 Infection (PASC) in a Large Academic
512 Medical Center in the US. *Journal of Clinical Medicine*, 12(4), 1328.
513 <https://doi.org/10.3390/jcm12041328>
- 514 16. Pfaff, E. R., Madlock-Brown, C., Baratta, J. M., Bhatia, A., Davis, H., Girvin, A., Hill,
515 E., Kelly, E., Kostka, K., Lomba, J., McMurry, J. A., Wong, R., Bennett, T. D., Moffitt,

- 516 R., Chute, C. G., Haendel, M., The N3C Consortium, & The RECOVER Consortium.
517 (2023). Coding long COVID: Characterizing a new disease through an ICD-10 lens.
518 *BMC Medicine*, 21(1), 58. <https://doi.org/10.1186/s12916-023-02737-6>
- 519 17. International Classification of Diseases, Tenth Revision (ICD-10), World Health
520 Organization (WHO) 2019/2021. <https://icd.who.int/browse11>. Licensed under Creative
521 Commons Attribution-NoDerivatives 3.0 IGO license (CC BY-ND 3.0 IGO).
- 522 18. Centers for Disease Control and Prevention. Post-covid conditions: Information for
523 healthcare providers. Accessed January 5, 2024. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html)
524 [ncov/hcp/clinical-care/post-covid-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html)
- 525 19. Pfaff, E. R., Girvin, A. T., Bennett, T. D., Bhatia, A., Brooks, I. M., Deer, R. R.,
526 Dekermanjian, J. P., Jolley, S. E., Kahn, M. G., Kostka, K., McMurry, J. A., Moffitt, R.,
527 Walden, A., Chute, C. G., Haendel, M. A., Bramante, C., Dorr, D., Morris, M., Parker, A.
528 M., ... Niehaus, E. (2022). Identifying who has long COVID in the USA: A machine
529 learning approach using N3C data. *The Lancet Digital Health*, 4(7), e532–e541.
530 [https://doi.org/10.1016/S2589-7500\(22\)00048-6](https://doi.org/10.1016/S2589-7500(22)00048-6)
- 531 20. Lorman, V., Razzaghi, H., Song, X., Morse, K., Utidjian, L., Allen, A. J., Rao, S.,
532 Rogerson, C., Bennett, T. D., Morizono, H., Eckrich, D., Jhaveri, R., Huang, Y., Ranade,
533 D., Pajor, N., Lee, G. M., Forrest, C. B., & Bailey, L. C. (2023). A machine learning-
534 based phenotype for long COVID in children: An EHR-based study from the RECOVER
535 program. *PLOS ONE*, 18(8), e0289774. <https://doi.org/10.1371/journal.pone.0289774>
- 536 21. RECOVER: Researching COVID to Enhance Recovery. RECOVER: Researching
537 COVID to Enhance Recovery. <https://recovercovid.org>. Accessed 4 Jan 2024.

- 538 22. Mejias A, Schuchard J, Rao S, Bennett TD, Jhaveri R, Thacker D, Bailey LC, Christakis
539 DA, Pajor NM, Razzaghi H, Forrest CB, Lee GM. Leveraging Serologic Testing to
540 Identify Children at Risk for Post-Acute Sequelae of SARS-CoV-2 Infection: An
541 Electronic Health Record-Based Cohort Study from the RECOVER Program. *J Pediatr.*
542 2023 Jun; 257:113358. doi: 10.1016/j.jpeds.2023.02.005.
- 543 23. PA Harris, R Taylor, R Thielke, J Payne, N Gonzalez, JG. Conde, Research electronic
544 data capture (REDCap) – A metadata-driven methodology and workflow process for
545 providing translational research informatics support, *J Biomed Inform.* 2009
546 *Apr;42(2):377-81.*
- 547 24. Posit team (2023). RStudio: Integrated Development Environment for R. Posit Software,
548 PBC, Boston, MA. URL <http://www.posit.co/>.
- 549 25. Simon, T. D., Lawrence, M., Stanford, S., Lyons, D., Woodcox, P., Hood, M., & Chen,
550 A. Y. (2014). Pediatric Medical Complexity Algorithm: A New Method to Stratify
551 Children by Medical Complexity. *Pediatrics*, 133(6).
- 552 26. Wang, L., Davis, P. B., Berger, N., Kaelber, D. C., Volkow, N., & Xu, R. (2023).
553 Association of COVID-19 with respiratory syncytial virus (RSV) infections in children
554 aged 0-5 years in the USA in 2022: a multicenter retrospective cohort study. *Family*
555 *medicine and community health*, 11(4), e002456. [https://doi.org/10.1136/fmch-2023-](https://doi.org/10.1136/fmch-2023-002456)
556 [002456](https://doi.org/10.1136/fmch-2023-002456)
- 557 27. Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-
558 19 versus seasonal influenza: a cohort study. *Lancet Infect Dis.* 2023 Dec 14: S1473-
559 3099(23)00684-9. doi: 10.1016/S1473-3099(23)00684-9.

560 28. World Health Organization. (2019). 8D89.2 Postural orthostatic tachycardia syndrome.
561 In *International statistical classification of diseases and related health problems* (11th
562 ed.). <https://icd.who.int/browse/2024-01/mms/en#1533647472>

563

564

565

566

567

568

569

570

571

572


573

574

575

576


577




578 *CED = cohort entry date

579 **Figure 1.** Study Timeline.

580



581
582 **Figure 2.** Flow chart depicting attrition and algorithm used to identify patients with Long COVID.



583

584 **Figure 3.** Sampling strategy for the chart review cohort. The numbers reported in parentheses
 585 represent sample sizes.

586

587

588

589

590

591

592

593

594

595

596 **Table 1.** Demographics of children with and without Long COVID based on the computable
 597 phenotype definition.

	CP-Detected Long COVID (N=318)	No CP-Detected Long COVID (N=333)	Overall (N=651)
<i>Approx. CED age (years)</i>			
Mean (SD)	10.10 (6.32)	10.10 (6.28)	10.10 (6.30)
Median [Min, Max]	11.0 [0, 21.0]	10.3 [0.1, 21.0]	10.9 [0, 21.0]
<i>CED Age Group (years)</i>			
<1	24 (7.5%)	25 (7.5%)	49 (7.5%)
1-4	70 (22.0%)	76 (22.8%)	146 (22.4%)
5-9	52 (16.4%)	55 (16.5%)	107 (16.4%)
10-15	98 (30.8%)	100 (30.0%)	198 (30.4%)
16-20	74 (23.3%)	77 (23.1%)	151 (23.2%)
<i>Patient Sex</i>			
Male	147 (46.2%)	167 (50.2%)	314 (48.2%)
Female	171 (53.8%)	166 (49.8%)	337 (51.8%)
<i>Race</i>			
Asian/Native Hawaiian/Pacific Islander	12 (3.8%)	14 (4.2%)	26 (4.0%)
Black	57 (17.9%)	58 (17.4%)	115 (17.7%)
White	175 (55.0%)	182 (54.7%)	357 (54.8%)
Multiracial	12 (3.8%)	9 (2.7%)	21 (3.2%)
Unknown	62 (19.5%)	70 (21.0%)	132 (20.3%)
<i>Ethnicity</i>			
Hispanic	78 (24.5%)	99 (29.7%)	177 (27.2%)
Non-Hispanic	214 (67.3%)	210 (63.1%)	424 (65.1%)
Unknown	26 (8.2%)	24 (7.2%)	50 (7.7%)
<i>Payer*</i>			
Private	139 (43.7%)	143 (42.9%)	282 (43.3%)
Public	124 (39.0%)	134 (40.2%)	258 (39.6%)
Other/Unknown	55 (17.3%)	56 (16.8%)	111 (17.1%)

598 *Note. CP = computable phenotype. *=at time of COVID-19 infection.*

599

600

601

602 **Table 2.** Statistics comparing computable phenotype and clinician review identification of Long
603 COVID.

	CR-Positive (N = 239)	CR-Negative (N = 412)				
CP-Positive (N = 318)	156	162				
CP-Negative (N = 333)	83	250				
Performance Statistics*						
	Accuracy	Sensitivity	Specificity	PPV	NPV	F1
	0.624	0.653	0.607	0.491	0.751	0.560

604 Note. PPV = positive predictive value. NPV = negative predictive value. CP = computable
605 phenotype. CR = chart review.

606 *Reported as CP relative to CR.

607

608

609


610

611

612

613

614



615

616 **Figure 4.** *Qualitative review of a.) CP+/CR- Long COVID patients and b.) CR+/CP- Long*

617 *COVID patients.*

618

619

620

621

622

623

624

625

626

627

628 **Table 3.** Statistics comparing modified computable phenotype and clinician review identification
 629 of Long COVID.

Modified						
	CR-Positive (N = 239)	CR-Negative (N = 412)				
Modified CP-Positive (N=188)	123	65				
Modified CP-Negative (N=463)	116	347				
No Medically Complex Patients						
	CR-Positive (N = 210)	CR-Negative (N = 308)				
Modified CP-Positive (N = 188)	123	65				
Modified-CP Negative (N = 330)	87	243				
Performance Statistics*						
	Accuracy	Sensitivity	Specificity	PPV	NPV	F1
Modified	0.722	0.515	0.842	0.654	0.749	0.576
No Medically Complex Patients	0.707	0.586	0.789	0.654	0.736	0.618

630 Note. PPV = positive predictive value. NPV = negative predictive value. CP = computable
 631 phenotype. CR = chart review.

632 *Reported as CP relative to CR

633